Abstract
Staphylococcus aureus remains one of the leading causes of infections worldwide and a common cause of bacteremia. However, studies documenting the epidemiology of S. aureus in South America (SA) using genomics are scarce. We hereby report on the largest to date genomic epidemiology study of both methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) in SA, conducted by the StaphNET-SA network. We characterised 404 genomes recovered from a prospective observational study of S. aureus bacteremia in 58 hospitals from Argentina, Bolivia, Brazil, Paraguay and Uruguay between April and October 2019.
We show that a minority of S. aureus isolates are phenotypically multi-drug resistant (5.2%), but more than a quarter are resistant to macrolide-lincosamide-streptogramin B (MLSb). MSSA were more genetically diverse than MRSA. Lower rates of associated antimicrobial resistance in CA-MRSA vs HA-MRSA were found in association with three S. aureus genotypes dominating the MRSA population: CC30-MRSA-IVc-t019-lukS/F-PV+, CC5-MRSA-IV-t002-lukS/F-PV-, and CC8-MRSA-IVc-t008-lukS/F-PV+-COMER+. These are historically from a CA origin, carry on average less AMR determinants, and often lack key virulence genes.
Surprisingly, CC398-MSSA-t1451-lukS/F-PV- related to the CC398 human-associated lineage is widely disseminated throughout the region, and is described here for the first time as the most prevalent MSSA lineage in SA. Moreover, CC398 strains carrying ermT and sh_fabI (related to triclosan resistance) were recovered from both CA and HA origin, and are largely responsible for the MLSb rates of MSSA strains (inducible iMLSb phenotype).
The frequency of MRSA and MSSA lineages differed between countries but the most prevalent S. aureus genotypes are high-risk clones widespread in the South American region without clear country-specific phylogeographic structure. Therefore our findings underscore the need for continuous genomic surveillance by regional networks such as StaphNET-SA.
Impact statement S. aureus is a common cause of bacteremia, a serious life threatening disease, and the second leading pathogen for deaths associated with resistance in 2019. However, genomic surveillance of S. aureus causing invasive infections in South America is limited. Previous surveillance studies have focused on the dissemination of MRSA with increasing AMR and/or virulence, but have not characterised MSSA in detail.
Here, we show the results of a prospective observational study of genomic surveillance of S. aureus causing bacteremia conducted in South America during 2019 by the StaphNET-SA network.
Our study reveals that in 2019 most bloodstream infections were caused by successful MRSA lineages of community origin, generally not MDR, and lacking key virulence genes in some cases. Importantly, we also describe here for the first time CC398-MSSA-t1451 as the most prevalent and widely disseminated MSSA clone causing bacteraemia in the region during 2019. This human adapted clone, present both in the community and hospital environment, carries a gene conferring resistance against an antiseptic widely used in our region, and is largely responsible for the increasing resistance rates to erythromycin and clindamycin observed in MSSA.
We also show evidence of readily transmission of the most prevalent MRSA and MSSA high-risk clones across country borders, which highlights the need for continuous genomic surveillance by regional networks such as StaphNET-SA.
Data Summary All supporting data, code and protocols have been provided within the article or through supplementary data files. Five supplementary figures and five supplementary tables are available with the online version of this article.
Sequence read files for all samples used in this study have been deposited in the European Nucleotide Archive under the project accession number PRJEB37318. Individual accession numbers for each sample are also detailed in microreact_project: https://microreact.org/project/staphnet-sa-1st-survey. Genome assemblies are available via Pathogenwatch https://pathogen.watch/collection/jz7rcy1zv0sk-staphnet-sa-first-survey.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was supported by grants from The Academy of Medical Sciences and GCRF to M.M. and D.M.A. (GCRFNG100309 networking grant), University of Buenos Aires (UBACYT 2018-2020- 20020170100665BA), CONICET (PIP 2015 11220150100694CO) and ANPCYT (Prestamo BID PICT-2016-1726 and PICT2020-03132) to M.M. and (Prestamo BID PICT-2018-03068) to S.D.G, The National Institute for Health Research (UK) Global Health Research Unit on genomic Surveillance of AMR (16_136_111) to D.M.A. and the Centre for Genomic Pathogen Surveillance (http://pathogensurveillance.net).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of the School of Pharmacy and Biochemistry of the University of Buenos Aires (RES (CD) Number 818-19 CEIC - FFYB-UBA) gave ethical approval for this work. The study was non-interventional, and cases were managed clinically both in terms of diagnosis and treatment according to standard care guidelines. Patients' personal identifiable information (name, dob, address) was not provided for this study. Informed written consent was not required, since the information was anonymized and the medical management and the diagnostic procedures were not affected.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Repositories: Sequence read files for all samples used in this study have been deposited in the European Nucleotide Archive under the project accession number PRJEB37318.
Data Availability
All supporting data, code and protocols have been provided within the article or through supplementary data files. Five supplementary figures and five supplementary tables are available with the online version of this article. Sequence read files for all samples used in this study have been deposited in the European Nucleotide Archive under the project accession number PRJEB37318.
